locanabio-logo-rgb.jpg
Locanabio Presents Preclinical Data from its Vectorized snRNA Exon Skipping Program for DMD and Cas13d Multi-targeting Program for C9orf72 ALS at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
May 16, 2023 06:00 ET | Locanabio, Inc.
LBIO-115 demonstrates robust exon 51 skipping resulting in high levels of dystrophin restoration in patient-derived muscle cells and an in vivo DMD disease model Cas13d Multi-targeting efficiently...
Outpace Bio, a Leader in Protein Design for Cell Therapy, Announces Presentation at the 2023 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
May 09, 2023 09:00 ET | Outpace Bio
Seattle, WA, May 09, 2023 (GLOBE NEWSWIRE) -- Outpace Bio, a company using protein design and cell engineering to create advanced cell therapies with curative potential, today announced that an...
NKGen Biotech RGB small.jpg
NKGen Biotech to Present at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting
May 02, 2023 16:35 ET | NKGen Biotech
SANTA ANA, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (“NKGen”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous,...
3787276_Codiak_Logo_White_CMYK.jpg
Codiak Presents New Preclinical Data at ASGCT 2022 on Exosome-Based Strategy to Enhance AAV Gene Therapy
May 17, 2022 07:00 ET | Codiak BioSciences, Inc.
CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a...
Caribou Logo.png
Caribou Biosciences Presents Data on Mechanism Underlying Superior Specificity of Caribou’s chRDNA Genome-Editing Technology in Primary Human T cells
May 16, 2022 16:05 ET | Caribou Biosciences, Inc.
BERKELEY, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the...
ShapeTX_Logo_BLUE.png
Shape Therapeutics to Present Data Highlighting Advances in Its AI-Driven RNA Technology Platforms at the 2022 ASGCT Annual Meeting
May 12, 2022 08:00 ET | Shape Therapeutics, Inc.
SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Shape Therapeutics® Inc. the RNA technology company advancing programmable medicine, today announced new data from its RNAfix®, RNAskipTM and AAVidTM...
Otonomy, Inc. Logo
Otonomy Announces OTO-825 Presentation at the American Society of Gene & Cell Therapy Annual Meeting
May 12, 2022 07:30 ET | Otonomy, Inc.
SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
Freeline_Logo_Red_RGB.jpg
Freeline To Present at the 25th Annual Meeting of the American Society of Gene and Cell Therapy
May 02, 2022 17:10 ET | Freeline Therapeutics
LONDON, May 02, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced the upcoming presentation of five posters at the 25th Annual...
Logo-uniQure-MS-Word_Orange.jpg
uniQure Announces Multiple Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
May 02, 2022 16:45 ET | uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, May 02, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
Autolus-Logo_Bright_Blue-–-RGB.png
Autolus Therapeutics to Present Three Novel Cell Programming Approaches at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting, May 16-19, 2022 
May 02, 2022 16:31 ET | Autolus Therapeutics plc
LONDON, May 02, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces...